Gene editing and imaging techniques for treating juvenile macular degeneration
Therapeutic gene editing and multimodal imaging in juvenile macular degeneration
This study is exploring new gene editing methods to help treat juvenile macular degeneration, a condition that can affect your vision, by fixing or removing the faulty genes causing the problem, and it aims to make the treatment easier for different genetic issues while keeping track of how well it works.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10877056 on NIH RePORTER |
What this research studies
This research focuses on developing advanced gene editing techniques, specifically using CRISPR/Cas9, to treat juvenile macular degeneration, a condition that can lead to vision loss. The approach aims to repair or remove malfunctioning genes responsible for the disease, particularly targeting mutations in the BEST1 gene. By utilizing a novel mutation nonspecific strategy, the research seeks to simplify the treatment process for various genetic mutations that cause this condition. Patients may benefit from multimodal imaging to monitor the effectiveness of the treatment over time.
Who could benefit from this research
Good fit: Ideal candidates for this research are adolescents diagnosed with juvenile macular degeneration caused by specific genetic mutations.
Not a fit: Patients with juvenile macular degeneration not caused by genetic mutations targeted by this research may not receive any benefit.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking treatment option for patients suffering from juvenile macular degeneration, potentially restoring vision.
How similar studies have performed: Previous research using CRISPR technology has shown promise in treating genetic disorders, indicating potential success for this novel approach.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Tsang, Stephen H — Columbia University Health Sciences
- Study coordinator: Tsang, Stephen H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.